Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Gabriel Horta-Baas. (2022) Patient-Reported Outcomes in Rheumatoid Arthritis: A Key Consideration for Evaluating Biosimilar Uptake?. Patient Related Outcome Measures 13, pages 79-95.
Read now
Read now
Maurizio Benucci & Fabrizio Cantini. (2019) Non-medical switching: save today and pay tomorrow. Journal of Medical Economics 22:11, pages 1160-1161.
Read now
Read now
Dae Hyun Yoo, Jung-Yoon Choe, Seung Cheol Shim & Chang-Hee Suh. (2018) Switching to biosimilars in the treatment of rheumatic diseases. Expert Review of Clinical Immunology 14:7, pages 557-571.
Read now
Read now
Articles from other publishers (18)
Yifei Liu, Martha Skup, Min Yang, Cynthia Z. Qi & Eric Q. Wu. (2022) Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018. Advances in Therapy 39:8, pages 3711-3734.
Crossref
Crossref
Andrea Becciolini, Simone Parisi, Rosalba Caccavale, Elena Bravi, Federica Lumetti, Romina Andracco, Alessandro Volpe, Lucia Gardelli, Francesco Girelli, Eleonora Di Donato, Daniele Santilli, Gianluca Lucchini, Maria Chiara Ditto, Ilaria Platè, Eugenio Arrigoni, Flavio Mozzani, Michele Riva, Antonio Marchetta, Enrico Fusaro, Gilda Sandri, Carlo Salvarani, Marino Paroli & Alarico Ariani. (2022) Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis. Journal of Personalized Medicine 12:3, pages 335.
Crossref
Crossref
Rosanne W. Meijboom, Helga Gardarsdottir, Toine C. G. Egberts & Thijs J. Giezen. (2021) Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review. BioDrugs 36:1, pages 27-39.
Crossref
Crossref
Miguel Ángel Abad Hernández, José Luis Andreu, Alejandro Balsa Criado, Federico Díaz-González, José Vicente Moreno Muelas, Rubén Queiro Silva & Juan J. Gómez-Reino. (2021) Update of the position paper of the Spanish Society of Rheumatology on biosimilar drugs. Reumatología Clínica (English Edition) 17:3, pages 160-169.
Crossref
Crossref
Miguel Ángel Abad Hernández, José Luis Andreu, Alejandro Balsa Criado, Federico Díaz-González, José Vicente Moreno Muelas, Rubén Queiro Silva & Juan J. Gómez-Reino. (2021) Actualización del Documento de posicionamiento de la Sociedad Española de Reumatología sobre fármacos biosimilares. Reumatología Clínica 17:3, pages 160-169.
Crossref
Crossref
Brian G. Feagan, Mona Marabani, Jashin J. Wu, Freddy Faccin, Claire Spronk & Gilberto Castañeda-Hernández. (2020) The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence. Advances in Therapy 37:11, pages 4491-4518.
Crossref
Crossref
Seung Wook Hong, Yong-Gil Kim & Byong Duk Ye. (2020) An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases. Immunotherapy 12:9, pages 609-623.
Crossref
Crossref
Roy Fleischmann, Vipul Jairath, Eduardo Mysler, Dave Nicholls & Paul Declerck. (2020) Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?. Rheumatology and Therapy 7:1, pages 35-64.
Crossref
Crossref
Hyoun-Ah Kim, Eunyoung Lee, Sun-Kyung Lee, Yong-Beom Park, Young Nam Lee, Hee Jung Kang & Kichul Shin. (2019) Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry. BioDrugs 34:1, pages 89-98.
Crossref
Crossref
Jason Chau, Thomas Delate, Taylor Ota & Bharati Bhardwaja. (2019) Patient Perspectives on Switching from Infliximab to Infliximab‐dyyb in Patients with Rheumatologic Diseases in the United States. ACR Open Rheumatology 1:1, pages 52-57.
Crossref
Crossref
Georgios Bakalos & Elias Zintzaras. (2019) Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review. Clinical Therapeutics 41:1, pages 155-173.e13.
Crossref
Crossref
Evrydiki Kravvariti, George D. Kitas, Dimos D. Mitsikostas & Petros P. Sfikakis. (2018) Nocebos in rheumatology: emerging concepts and their implications for clinical practice. Nature Reviews Rheumatology 14:12, pages 727-740.
Crossref
Crossref
Johlee S. OdinetChelsea E. DayJennifer L. CruzGregory A. Heindel. (2018) The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies. Journal of Managed Care & Specialty Pharmacy 24:10, pages 952-959.
Crossref
Crossref
Syed Numan & Freddy Faccin. (2018) Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies. Advances in Therapy 35:9, pages 1295-1332.
Crossref
Crossref
Jose-Manuel Carrascosa, Ira Jacobs, Danielle Petersel & Robert Strohal. (2018) Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future. Dermatology and Therapy 8:2, pages 173-194.
Crossref
Crossref
Bassel El Zorkany, Nizar Al Ani, Samar Al Emadi, Jamal Al Saleh, Imad Uthman, Yasser El Dershaby, Mohamed Mounir & Hani Al Moallim. (2018) Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries. Clinical Rheumatology 37:5, pages 1143-1152.
Crossref
Crossref
Ross A. McKinnon, Matthew Cook, Winston Liauw, Mona Marabani, Ian C. Marschner, Nicolle H. Packer & Johannes B. Prins. (2018) Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review. BioDrugs 32:1, pages 27-52.
Crossref
Crossref
Robert Moots, Valderilio Azevedo, Javier L. Coindreau, Thomas Dörner, Ehab Mahgoub, Eduardo Mysler, Morton Scheinberg & Lisa Marshall. (2017) Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician. Current Rheumatology Reports 19:6.
Crossref
Crossref